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Abstract: Despite the ever-rising incidence of Gestational Diabetes Mellitus (GDM) and its
implications for long-term health of mothers and offspring, the underlying molecular mechanisms
remain to be elucidated. To contribute to this, the present study’s objectives are to conduct a
sex-specific analysis of active histone modifications in placentas affected by GDM and to investigate
the effect of calcitriol on trophoblast cell’s transcriptional status. The expression of Histone H3
lysine 9 acetylation (H3K9ac) and Histone H3 lysine 4 trimethylation (H3K4me3) was evaluated in
40 control and 40 GDM (20 male and 20 female each) placentas using immunohistochemistry and
immunofluorescence. The choriocarcinoma cell line BeWo and primary human villous trophoblast
cells were treated with calcitriol (48 h). Thereafter, western blots were used to quantify concentrations
of H3K9ac and the transcription factor FOXO1. H3K9ac expression was downregulated in GDM
placentas, while H3K4me3 expression was not significantly different. Cell culture experiments
showed a slight downregulation of H3K9ac after calcitriol stimulation at the highest concentration.
FOXO1 expression showed a dose-dependent increase. Our data supports previous research
suggesting that epigenetic dysregulations play a key role in gestational diabetes mellitus. Insufficient
transcriptional activity may be part of its pathophysiology and this cannot be rescued by calcitriol.
Keywords: histone modification; H3K9ac; H3K4me3; FOXO1; epigenetics; gestational diabetes;
vitamin D
1. Introduction
Gestational Diabetes Mellitus (GDM) is defined as glucose intolerance firstly detected during
pregnancy [1]. It is the most common pregnancy-related metabolic disorder, affecting up to 14% of
pregnancies [2]. Contrary to other obstetric complications, its prevalence has increased steadily over
the past decades, making it an urgent issue in pre- and perinatal care [3,4].
The short-term consequences of GDM include a higher risk for preeclampsia (Odds Ratio (OR)
1.81), large for gestational age infants (LGA) (OR 3.43) and C-section (OR 1.46) [5,6]. However,
GDM also affects long-term health outcomes of both mothers and offspring. Women who suffered
from GDM stand a substantially higher risk of developing diabetes mellitus type 2 (DM2) later in life
(relative risk (RR) 7.43) [7]. Their offspring also suffer from a higher risk for developing metabolic
syndrome, DM2, adiposity and cardiovascular disease [8–10].
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GDM manifests when the increased need for insulin during pregnancy cannot be met, leading
to a state of glucose intolerance, insulin resistance and inflammation similar to DM2 [11,12]. As the
producer of anti-insulin hormones and in its function as the foeto-maternal-interface, the placenta is
thought to play a key role in the pathophysiology of GDM in general and, more specifically, in the
long-term health programming of the offspring [13,14]. However, despite the urgent need for effective
treatment and disease prevention in future generations, the pathophysiology’s underlying molecular
mechanisms are not yet fully understood.
Increasingly, pathophysiological research focuses on transcriptional and epigenetic mechanisms of
insulin resistance. Evidence constantly emerges that transcription factors, including FOXO1, co-factors
and chromatin modifications, like post-translational histone modifications, interact on various levels
of gene expression and through this, contribute to insulin resistance. These mechanisms may also be
part of the developmental programming of metabolic diseases [15].
Barker’s “Developmental Origins of Human Health and Disease” theory, stating that foetal
environment influences health outcomes in later life, first arose from investigations of the relationship
between birthweight and cardiovascular diseases in adulthood [16,17]. Since then, results from various
cell culture and animal models, as well as epidemiological investigations point towards epigenetics as
being one of the underlying molecular mechanisms [18–21].
Epigenetics can be seen as “the sum of the alterations to the chromatin template that collectively
establish and propagate different patterns of gene expression and silencing from the same genome” [22].
The three main mechanisms interacting to form the epigenome are: DNA methylation, histone
modifications and non-coding RNA (ncRNA) [22]. While evidence of epigenetic changes in GDM
cases is growing, research has been focusing mainly on DNA methylation studies, with data on histone
modifications in GDM is still widely lacking [23].
Post-translational Modification (PTM) of histone proteins influences transcription, DNA
replication and other processes via cis and/or trans mechanisms. The direct cis mechanism describes
a change of inter-nucleosome contact, thus affecting the chromatin condensation state. Histone
acetylation is known to have a vast potency for unfolding chromatin. The indirect trans mechanism
refers to the recruitment of “reader” proteins to the chromatin, which in turn recruit further modifying
proteins. Additionally, to cis and trans interactions, interaction between different PTMs, so called
“cross-talk”, also occur [22,24,25]. As the “cross-talk” interactions indicate, the sum of histone
modifications results in a histone-code, which determines the accessibility of a given chromatin section.
The two modifications acetylation of histone 3 at lysine 9 (H3K9ac) and trimethylation of histone
3 at lysine 4 (H3K4me3) are known to be “active” modifications, and their presence at Transcriptional
Start Site (TSS) regions correlates with the amplitude of gene expression [26]. High levels of H3K4me3
can be found specifically at the promotor region of active genes, because it plays a role in forming
the preinitiation complex [27,28]. H3K9ac enrichment, on the other hand, marks active enhancers.
Furthermore, both PTMs are found at bivalent promoters marking regulatory genes of importance for
cell differentiation [26,29]. These findings indicate that both H3K9ac and H3K4me3, like epigenetics
in general, are of great importance for an organism’s development and human disease. Their role in
GDM, however, has not yet been investigated.
FOXO1 is part of the Forkhead box protein subfamily O, a group of transcription factors containing
winged helix DNA-binding domain [30]. In its function as a transcription factor, it plays a key role
in metabolic regulation, especially in the glucose metabolism. Increased FOXO1 has been shown to
stimulate gluconeogenesis as well as lipid production in liver cells [31,32]. Reduced FOXO1 function
on the other hand was shown to protect against insulin resistance under a high fat diet in mice [33].
More recent results were able to show that FOXO1 is elevated in GDM placentas on mRNA as well
protein level. Furthermore, placental FOXO1 mRNA expression was significantly correlated with the
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) in the GDM group [34]. Further
studies with vitamin D receptor (VDR) knockout mice extrapolated a functional link between vitamin
D deficiency, elevated FOXO1 and insulin resistance in muscle cells [35].
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The epidemiological connection between vitamin D deficiency and GDM has been discussed,
but remains controversial, with several studies suggesting that there is a positive correlation between
low vitamin D and insulin resistance or GDM respectively [36–38], while others did not find a
significant connection [39–41]. Recent metanalyses suggest, however, that vitamin D deficiency is in fact
a risk factor (OR) for the development of GDM [42,43]. Investigations on GDM placentas have shown
an increased expression of VDR compared to control placentas and hypothesised this to be a reaction to
low vitamin D levels [44]. Recently, ChiP-seq analyses in cell culture experiments by Meyer, et al. [45]
showed that stimulation with Calcitriol (1,25(OH)2D3) lead to an enrichment of H3K9ac at promotor
regions of VDR regulated genes, suggesting a link between epigenetic modifications and vitamin D.
The aim of this study was to conduct a systematic, sex-specific immunohistochemical and
immunofluorescence analysis of active histone modifications in GDM placentas. Furthermore,
cell culture experiments were carried out to test the hypothesis that vitamin D stimulation could
increase H3K9ac and correspondingly decrease FOXO1 expression in the choriocarcinoma cell line
BeWo. Cell culture results were verified using primary human villous trophoblast (HVT) cultures.
We found H3K9ac to be upregulated in syncytiotrophoblast, extra villous trophoblast (EVT),
as well as foetal endothelial cells in GDM placentas. The analysis of H3K4me3 did not reveal
any significant differences in expression between GDM and control placentas. The stimulation of
BeWo cells with human calcitriol resulted in a decrease of H3K9ac at high concentrations and no
significant changes at low concentrations. This corresponded with an increase in FOXO1 expression
after stimulation. This indicates that the dysregulated H3K9ac expression in GDM cannot be salvaged
by vitamin D.
2. Results
The expression of specific post-translational modifications of histone protein 3 were analysed
in placental tissue from 40 heathy (20 of female, 20 of male foetuses) and 40 GDM pregnancies
(20 of female, 20 of male foetuses) using immunohistochemistry and double immunofluorescence.
The modifications under investigation were H3 lysine 9 acetylation (H3K9ac) and H3 lysine 4
trimethylation (H3K4me3).
2.1. H3K9ac Expression is Downregulated in GDM Placentas
There was no sex-specific difference of H3K9ac expression within the control group, nor within
the GDM group. Therefore, we grouped male and female data of control and GDM group for the
following data analysis. A very strong H3K9ac expression (median immuno reactive score (IRS):
12) was detected in nuclei of villous syncytiothrophoblast cells (SCT), extra villous trophoblast cells
(EVT) as well as foetal endothelial cells in control placentas. The boxplot in Figure 1A illustrates that
the expression of H3K9ac was significantly downregulated in the syncytiotrophoblast cells of GDM
placentas (p < 0.001), with a median IRS of 12 in the control compared to 8 in the GDM placentas.
The same pattern was found in EVTs (Figure 1D–F) and foetal endothelial cells (Figure 1G–I), where
statistical analysis proved the downregulation to be highly significant (p < 0.001).
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Figure 1. H3K9ac expression in syncytiotrophoblast, decidua and foetal endothelia cells of control 
and GDM placentas. Boxplots (A,D,G) showing the IRS for H3K9ac expression in syncytiotrophoblast 
(SCT), decidua and foetal endothelial to be highly significantly lower in GDM placentas (p < 0.001). 
The range between the 25th and 75th percentiles is represented by the boxes with the horizontal line 
showing median. The bars indicate the 5th and 95th percentiles. Circles indicate values more than 1.5-
times the boxes’ lengths. Pictures showing representative slides for immunohistochemical staining of 
H3K9ac in the SCT (control (B,b); GDM (C,c)), decidua (control (E,e); GDM (F,f)) and foetal 
endothelial cells (control (H,h); GDM (I,i)) of according placentas. Arrowheads indicate foetal 
endothelial cells. Pictures were taken with a 100× lens (capital letters) and 250× lens (lower-case letters) 
respectively. 
2.2. No Difference between H3K4me3 Expression in GDM and Control Placentas 
In contrast to H3K9ac expression, no statistically significant differences were found in the 
expression of H3K4me3 (see Figure S1). The median IRS for H3K4me3 expression in the 
syncytiotrophoblast was 8 in control, as well as GDM placentas (p = 0.853). Similar results were 
obtained for EVTs. There was however a significant difference in the H3K4me3 expression between 
male and female control placentas (p = 0.040). 
2.3. Identification of H3K9ac Expressing Cells by Immunofluorescence Double Staining 
Figure 1. H3K9ac expression in syncytiotrophoblast, decidua and foetal endothelia cells of control
and GDM placentas. Boxplots (A,D,G) showing the IRS for H3K9ac expression in syncytiotrophoblast
(SCT), decidua and foetal endothelial to be highly significantly lower in GDM placentas (p < 0.001).
The range between the 25th and 75th percentiles is represented by the boxes with the horizontal
line showing median. The bars indicate the 5th and 95th percentiles. Circles indicate values more
than 1.5-times the boxes’ lengths. Pictures showing representative slides for immunohistochemical
staining of H3K9ac in the SCT (control (B,b); GDM (C,c)), decidua (control (E,e); GDM (F,f)) and
foetal endothelial cells (control (H,h); GDM (I,i)) of according placentas. Arrowheads indicate foetal
endothelial cells. Pictures were taken with a 100× lens (capital letters) and 250× lens (lower-case
letters) respectively.
2.2. No Differ nce between H3K4me3 Expression in GDM and Control Placentas
In contrast to H3K9ac expression, no statistically significant differences were found in the
expression of H3K4me3 (see Figure S1). The median IRS for H3K4me3 expression in the
syncytiotrophoblast was 8 in control, as well as GDM placentas (p = 0.853). Similar results wer
obtained for EVTs. There was however a significant difference in the expres ion between
male and female control placentas (p = 0.040).
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2.3. Identification of H3K9ac Expressing Cells by Immunofluorescence Double Staining
Immunofluorescence double staining was carried out using Cytokeratin 7 (CK7) and Cluster of
differentiation 31 (CD31) as identifying markers for EVTs and foetal endothelial cells respectively.
By using triple filter excitation microscopy, cell phenotypes could be identified (Figure 2).
Double filter excitation showed CK7 and H3K9ac expression in the same cell, thus confirming the
expression of H3K9ac by EVTs. H3K9ac was also expressed by some CK7-negative decidual stroma
cells. The H3K9ac expression was more intense in EVT cells of control placentas than GDM placentas.
Similarly, double filter excitation showed co-expression of CD31 and H3K9ac, confirming H3K9ac
expression by endothelial cells. Again, the H3K9ac expression was more intense in endothelial cells of
control placentas than GDM placentas.
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Figure 2. Double immunofluorescence phenotyping of placenta cells. H3K9ac, marked with Cy-3-
labled secondary antibody, is stained red in both rows. CK7 is stained green in the first row, marking 
EVT cells. CD31 is stained green in the second row, marking endothelial cells. Pictures were taken 
with a 400× lens. 
2.4. Downregulation of H3K9ac in Trophoblast Tumour Cells BeWo by Human Calcitriol (Vitamin D) 
To gain insight into the possible functional relationship between H3K9ac and FOXO1 expression 
and human calcitriol (Vit. D) Western Blot analysis was used to quantified H3K9ac expression in 
BeWo cells after Vit. D stimulation. 
Quantitative Western Blot analysis showed that the 48 h in vitro culture with 1.0 µM human 
calcitriol resulted in a significantly lower H3K9ac expression in BeWo cells (Figure 3B,C; p = 0.008). 
However, the stimulation with lower concentrations of human calcitriol (0.1 and 0.01 µM), though 
lowering H3K9ac expression slightly, did not have a significant influence on the expression of 
H3K9ac (p = 0.515 for both concentrations).  
Figure 2. Double immunofluorescence phenotyping of placenta cells. H3K9ac, marked with Cy-3-labled
secondary antibody, is stained red i bot rows. CK7 is st ined gr en in the first row, marking EVT
cells. CD31 is stained green in the second row, marking endothelial cells. Pictures were taken with a
400× lens.
2.4. Downregulation of H3K9ac in Trophoblast Tumour Cells BeWo by Human Calcitriol (Vitamin D)
To gain insight into the possible functional relation hip between H3K9 c and FOXO1 expression
and human calcitriol (Vit. D) Western Blot analysis was used to quantified H3K9ac expression in BeWo
cells after Vit. D stimulation.
Quantitative Western Blot analysis showed that the 48 h in vitro culture with 1.0 µM human
calcitriol resulted in a significantly lower H3K9ac expression in BeWo cells (Figure 3B,C; p = 0.008).
However, the stimulation with lower concentrations of human calcitriol (0.1 and 0.01 µM), though
lowering H3K9ac expression slightly, did not have a significant influence on the expression of H3K9ac
(p = 0.515 for both concentrations).
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2.5. Upregulation of FOXO1 in Trophoblast Tumour Cells BeWo by Human Calcitriol (Vitamin D)
The expression of FOXO1 in BeWo cells after vitamin D stimulation was found to increase in
a dose-dependent manner (Figure 3A,C). Statistical analysis showed the increased expression to be
significant (p = 0.011) even after stimulation with the lowest concentration (0.01 µM). FOXO1 expression
increased further with increasing concentrations of the stimulant, still showing statistical significance
(p = 0.021).
2.6. Downregulation of H3K9ac in Primary Human Villous Trophoblast Cells HVT by Human Calcitriol
(Vitamin D)
To solidify results concerning the downregulation of H3K9ac in BeWo cells, the experiment was
repeated using human villous trophoblast cells. The stimulation of primary culture human villous
trophoblast cells (HVT) with 1.0 µM human calcitriol showed an effect similar to BeWo cells. As seen
in Figure 4, the expression of H3K9ac was significantly decreased (p = 0.03) after a 48 h incubation in
comparison with the control culture.
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48 h stimulation with human calcitriol at 1.0 µM. (B) Representative photograph of the western blot
membrane with detected bands for H3K9 and endogenous control (β-Actin).
3. Discussio
Dysregulation of histone modifications is an important factor in the pathophysiology of metabolic
diseases and foetal programming, including GDM. The present study provides further evidence of
this, as we identified a significant downregulation of H3K9ac in syncytiotrophoblast, EVT and foetal
endothelial cells in GDM cases. Additional investigations of H3K4me3 did not show any dysregulation
in GDM placentas.
While studies on insulin resistance were able to identify changes in histone modifications on a
gene-specific level [46,47], this is the first study to show a pan-placental downregulation of H3K9ac in
gestational diabetes mellitus. H3K9ac is an important modification for transcription activity in general
and especially relevant for intrauterine development, synzytialisation and angiogenesis [26,48,49].
Animal studies have shown that treatment of somatic cell nuclear transfer embryos with histone
deacetylase (HDAC)-inhibitors and the corresponding increase in global H3K9ac levels lead to
improved embryo development and blastocyst quality [50]. Thus, the global H3K9ac downregulation
found in GDM may indicate insufficient capacity of gene expression. This reduction in transcriptional
activity could in turn be linked to foetal complications such as organ immaturity.
By now it has been well established that pregnancy-related diseases—including GDM—show
sex-specific differences in terms of pathophysiology and outcome [51,52]. Very recently,
Alexander, et al. [53] were able to show sex-specific differences in GDM on an epigenetic level. Thus,
we considered a sex-disaggregated collection of data to be of great importance for the present study.
The analysis of our data, however, did not show any sex-specific differences in H3K9ac expression.
Research investigating the “cross-talk” between H3K9ac and H3K4me3 indicates that acetylation
of H3 tails is dependent on the recognition of and binding to H3K4me3. Thus, H3K4me3 could
be seen as a docking basis for further activation of chromatin through H3 acetylation [54]. These
findings correspond with the PTM’s localizations. As mentioned before, H3K4me3 is an essential part
of the pre-initiation complex, forming the basis of transcription start, with transcription factor IID
(TFIID) selectively binding to H3K4me3. H3K9ac is part of active enhancers, and as such potentiates
transcription activity [55]. Taking this into account our findings may suggest that, while the basis for
gene transcription is still intact, the activation of chromatin is in fact impaired in GDM placentas.
Investigating the role of histone modifications in insulin resistance, studies on beta-cells showed
that treatment with incretin hormones, substances commonly used in treatment of DM2, leads to
a global increase in H3K9ac. This in turn leads to an increase in cAMP response element binding
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protein/CREB regulated transcription coactivator 2 (CREB/CRTC2) transcription factor activity [56],
indicating the functional relevance of H3K9ac. Since incretin generally improves insulin sensitivity,
these findings suggest that low H3K9ac levels may contribute to insulin resistance.
As outlined in the introduction, epidemiological as well as biochemical findings suggest a
functional relationship between vitamin D, H3K9ac and FOXO1 with potential relevance for GDM.
Thus, we hypothesized that treatment with vitamin D will positively affect H3K9ac (upregulate) and
FOXO1 (downregulate). This hypothesis was tested through cell culture experiments using BeWo cells
as a trophoblast model and HVT primary cultures to confirm (only H3K9ac). However, the results
refuted our hypothesis. H3K9ac expression was not affected by low doses of calcitriol and decreased
slightly at the highest concentration. FOXO1 expression increased after stimulation with calcitriol.
While these results are consistent within each other, they resemble a state of glucose resistance rather
than an improvement. Here it is important to note that stimulation of C2C12 muscle cells with calcitriol
did result in a downregulation of FOXO1, suggesting that its role in metabolic control is highly cell
type-specific [35]. We have summarized the immunohistochemical and cell culture findings graphically
in Figure 5.
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Figure 5. Two potential mechanisms leading to a reduction of H3K9ac in trophoblast cells. 
Immunohistochemical analysis showed a downregulation of H3K9ac (red triangle) in GDM placentas, 
while H3K4me3 (purple hexagons) showed no significant differences (solid pink arrow tail). The 
H3K9ac reduction may also be part of the aetiology of GDM (pink arrow broken line). Stimulation of 
trophoblast cells with calcitriol also lead to a reduction of H3K9ac, as well as an increase in FOXO1 
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while H3K4me3 (purple hexagons) showed no significant differences (solid pink arrow tail).
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foetal programming of cardiovascular disease associated with GDM. The role of H3K9ac in “metabolic
memory” of the vascular system is controversial. Chen, et al. [60] showed an increase of non-specific
H3 acetylation in human umbilical vein endothelial cells after glucose exposure. Furthermore, they
found that the overexpression of p300, a histone acetyltransferase (HAT), results in similar expression
profiles (e.g., transcription of VEGF-A and fibronectin) as glucose exposure. A global downregulation
of H3K9ac was, however, found in endothelium and, in general, in a state of hypoxia [61,62], which in
GDM may interact with the state of hyperglycaemia. Thus, further research is needed, concentrating
on functional pathways associated with the global downregulation of H3K9ac.
In conclusion, our findings corroborate the growing evidence that epigenetic dysregulations
play a key role in gestational diabetes mellitus. Due to the tremendous complexity of epigenetic
mechanisms, conclusions concerning functional implications are to be drawn with extreme caution.
The pan-placental downregulation of H3K9ac in GDM cases may, however, reflect a downregulation of
transcriptional activity. Whether this is cause or effect of the metabolic disorder needs to be investigated
further. Our cell culture experiments suggest that treatment with vitamin D is not sufficient to rescue
the epigenetic and transcriptional changes in GDM, making this another area where further research is
needed urgently.
4. Materials and Methods
4.1. Tissue Samples
The study design was approved by the Ludwig Maximilians University’s ethics committee and
written consent was obtained from all participating patients. All participants underwent an oral glucose
tolerance test (oGTT) between weeks 24 and 28 of their pregnancy. Using the criteria of the German
society for Diabetes Mellitus (capillary whole blood; fasting glucose >90 mg/dL, 1 h > 180 mg/dL,
and 2 h > 155 mg/dL) the diagnosis GDM was given when two measurements were above limits. For the
study design, 40 patients with GDM and 40 healthy patients (control) were chosen to participate. In each
group, foetal gender was balanced. For detailed information on clinical and epidemiological data see
Table 1. All GDM patients underwent insulin treatment and were monitored at least once a week at
the Diabetes Centre of the Department of Internal Medicine LMU Munich. The study was approved
by the ethical committee of the University of Munich (project identification code: 337-06) on the 26th of
August 2013 and informed consent was obtained from each patient in written form. Samples and clinical
information were anonymized for statistical workup.
Tissue samples (2 × 2 × 2 cm3) of the participants’ placentas were obtain directly after birth.
The pieces were taken from a cotyledon located the central part of placenta, with sufficient blood
supply, aiming to contain decidua, villous as well as extra villous trophoblasts and amniotic epithelia.
Areas showing signs of calcification, bleeding or ischemia were excluded from tissue collection. A 24 h
incubation period in 4% buffered formalin solution served to fixate the tissue samples, after which
they were embedded in paraffin for long-term storage.
Table 1. Clinical and epidemiological data of study participants. The Kruskal–Wallis and
Man-Whitney-U Tests were used for analysis of the data.
GDM Control p-Value
Male Female Male Female
Birthweight (g) 3662.1 ± 562 3635.9 ± 661 3339.8 ± 568 3294 ± 440 p = 0.019 *
Duration of gestation at delivery (weeks) 39.67 ± 1.30 39.83 ± 1.40 39.80 ± 1.54 39.75 ± 1.16 p = 0.943
Maternal BMI (pre-pregnancy) 29.38 ± 8.03 26.96 ± 4.73 21.92 ± 3.97 25.04 ± 7.90 p < 0.001 *
pH in umbilical artery 7.30 ± 0.07 7.30 ± 0.10 7.28 ± 0.10 7.30 ± 0.08 p = 0.826
Maternal Age (years) 31.46 ± 4.12 33.21 ± 5.33 30.30 ± 6.11 32.00 ± 6.13 p = 0.177
Vaginal delivery (%) 50 75 80 80 p = 0.207
Significant differences are marked with an asterisk (*).
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4.2. Immunohistochemistry
4.2.1. Staining
Immunohistochemical staining was carried out in accordance with the recently published protocol
by Hutter, et al. [63]. After blocking the endogenous peroxidase using 3% H2O2, the slides were
treated with sodium citrate (pH 6.0) in a high-pressure cooker in order to de-mask all protein
epitopes. To prevent any unspecific antigen-antibody interaction, blocking solution was applied
(ZytoChem Plus HRP Polymer System, Zytomed Systems GmBH, Berlin, Germany). The slides were
then incubated with the primary antibodies (see Table 2) for 16 h at 4 ◦C. Antigen-antibody interaction
was detected by applying the ZytoChem Plus HRP Polymer System (Zytomed Systems GmBH, Berlin,
Germany) in accordance with the manufacturer’s instructions. Chromogen 3,3’-diaminobenzidine
(DAB; Dako, Glostrup, Denmark) was used for staining followed by haemalaun for counterstaining.
After dehydration, the slides were cover-slipped. For each experiment, positive and negative control
staining was carried out on human colon tissue (Figure 6).
Table 2. Antibodies applied for immunohistochemistry and double-immunofluorescence.
Antibody Dilution Incubation Manufacturer
H3K4me3—polyclonal
Rabbit IgG 1:500 16 h at 4
◦C Abcam—ab8580 (Cambridge, UK)
H3K9ac—Clone Y28
Rabbit IgG 1:200 16 h at 4
◦C Abcam—ab32129 (Cambridge, UK)
CK7—Clone OVTL
Mouse IgG 1:30 16 h at 4
◦C Novocastra—NCL-L-CK7-OVTL (Newcastle, UK)
CD31—Clone JC/70A
Mouse IgG 1:50 16 h at 4
◦C Abcam—ab9498 (Cambridge, UK)
Cy-2-labelled goat-anti-rabbit 1:100 30 min at RT Dianova—115-226-062 (Hamburg, Germany)
Cy-3-labelled goat-anti-mouse 1:500 30 min at RT Dianova—111-165-144 (Hamburg, Germany)
1 
 
 
Figure 6. Positive and negative immunohistochemistry staining controls. Colon tissue was used as
positive (A,a) as well as negative (B,b) control for H3K9ac antibody. For the H3K4me3 antibody,
colon tissue was used as positive (C,c) as well as negative (D,d) control, as well. Negative control
serum was added to the tissue for negative control staining. Brown staining indicates primary and
secondary antibody binding, blue staining is due to haemalaun counter staining. Pictures were taken
at a 100× (capital letters) and 250× (lower-case letters) magnification, respectively.
4.2.2. Evaluation
Analysis of the tissue samples was conducted under a Leitz Diaplan microscope (Leitz, Wetzlar,
Germany). The semi-quantitative Immunoreactivity Score (IRS) [64] was used to evaluate tissue staining.
Multiplication of cell staining intensity (0: none; 1: weak; 2: moderate; 3: strong) with the percentage
of positively stained cells (0: no staining; 1: <10% of the cells; 2: 11–50%; 3: 51–80%; 4: >81%) results in
an IRS between 0 and 12 for each slide.
4.3. Double Immunofluorescence
To determine the phenotype of H3K9ac expressing cells in the placenta tissue, double
immunofluorescence staining was performed. Placenta tissue of both the control and the GDM
group were stained, using CK7 as a marker for EVTs and CD31 as a marker for foetal endothelial cells.
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Tissue samples from the same patient collective were used for double immunofluorescence
staining as for immunohistochemistry. Pre-treatment of the slides (deparaffinising, blocking of
endogenous peroxidase activity, de-masking of protein epitopes) was identical to that used for
immunohistochemistry. Blocking solution (Ultra V–Block, Thermo Scientific, Lab Vision, Fremont, CA,
USA) was applied for 15 min in order to prevent any unspecific antigen-antibody binding. Thereafter,
the primary antibodies were mixed and applied together (see Table 2). Following this, the slides were
incubated with the secondary antibodies (see Table 2) for 30 min. The slides were then cover-slipped
with minimal light exposure using mounting buffer (Vector Laboratories, Burlingame, CA, USA),
which contains DAPI for nuclear counterstaining. The phenotypes were analysed using the fluorescent
Axioskop photomicroscope (Zeiss, Oberkochen, Germany). Images were taken with a digital Axiocam
camera system (Zeiss, Oberkochen, German).
4.4. Cell Culture and Stimulation
The choriocarcinoma cell line BeWo (ECACC, Salisbury, UK) was used as a trophoblast model.
Human villous trophoblast cells (HVT) (ScienCell, Carlsbad, CA, USA), a primary cell culture which
was kryoconserved at −196 ◦C, was used to confirm BeWo results. Both cell lines were cultured in
DMEM (3.7 g/L NaHCO3, 4.5 g/L D-glucose, 1.028 g/L stable glutamine, and Na-Pyruvate; Biochrom,
Berlin, Germany) enriched with 10% foetal bovine serum (FBS) at 37 ◦C and 5% CO2. The BeWo
as well as the HVT cells were grown in a 12-well plate at a density of 500,000 cells/mL DMEM for
western blotting. To ensure adherence the cells were firstly cultured in DMEM with 10% FBS for 4 h,
after which it was replaced with fresh DMEM not containing any supplementation. Following the 24 h
incubation, the cells were stimulated with 0.01, 0.1 and 1.0 µM of human calcitriol (Sigma-Aldrich,
St. Louis, MO, USA), dissolved in ethanol and diluted in DMEM without FBS. Corresponding amounts
of ethanol were added to the control cells (see Table 3 for stimulation scheme). Stimulation lasted 48 h.
Table 3. Cell culture stimulation scheme.
BeWo Stimulation for Western Blot (WB)
1.0 µM Ethanol 0.01 µM Vit. D 0.1 µM Vit. D 1.0 µM Vit. D
HVT Stimulation for WB
1.0 µM Ethanol 1.0 µM Vit. D
4.5. Westernblotting of Stimulated BeWo Cells and HVT Cell
The cells were treated with 200 µL of lysis buffer for 30 min, consisting of RIPA
(Radioimmunoprecipitation assay buffer, Sigma-Aldrich, St. Louis, MO, USA) and protease inhibitor
(Sigma-Aldrich, St. Louis, MO, USA) (dilution 1:100). The obtained lysates were centrifuged.
To determine the protein concentration a Bradford assay was carried out. The amount of protein chosen
for β-Actin and H3K9ac/FOXO1 detection were 5 and 20–25 µg respectively. Firstly, the samples’
proteins were separated by molecular weight through sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) and thereafter transferred onto a polyvinylidene fluoride (PVDF)
membrane (Millipore, Billerica, MA, USA). Blocking of unspecific background staining was performed
by incubating the membrane in 1× Casein solution (VECTASTAIN ABC-AmP Kit for rabbit IgG,
Vector Laboratories, Burlingame, CA, USA) for 1 h. The primary antibodies, anti-H3K9ac (monoclonal
rabbit IgG, Abcam, Cambridge, UK), anti-FOXO1 (monoclonal mouse IgG, Novus Biologicals Europe,
Abingdon, UK) diluted at 1:500 in Casein and anti-β-Actin (monoclonal mouse IgG, Sigma-Aldrich,
St. Louise, MO, USA) diluted at 1:1000 in Casein, were added for 16 h at 4 ◦C, plus an additional
2 × 15 min incubation at room temperature for anti-H3K9ac and anti-FOXO1. Following washing in
1× Casein solution the membrane was incubated with the respective secondary antibodies, biotinylated
anti-rabbit-/mouse-IgG (VECTASTAIN ABC-AmP Kit for rabbit/mouse IgG, Vector Laboratories,
Burlingame, MA, USA) as instructed by manufacturer’s manual. After 20 min treatment with
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ABC-AmP-reagent (VECTASTAIN ABC-AmP Kit for rabbit IgG, Vector Laboratories, Burlingame, MA,
USA), the blots were developed with 5-bromo-4-chloro-3’-indolyphosphate/nitro-blue tetrazolium
(BCIP/NBT)-chromogen substrate solution (VECTASTAIN ABC-AmP Kit for rabbit IgG, Vector
Laboratories, Burlingame, MA, USA). Blots were detected using the Bio-Rad Universal Hood II
(Bio-Rad Laboratories, Hercules, CA, USA) and quantitative analysis was performed using Bio-Rad
Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
4.6. Statistical Analysis
IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA: IBM Corp was used for data
collection, data analysis and charts. More specifically, the non-parametric Mann-Whitney-U test was
used for comparison of IRS results and the Wilcoxon-signed rank test for analysis of western blot
results. P-values smaller than 0.05 were considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/12/
4061/s1. Figure S1: Sex-disaggregated H3K4me3 expression in syncytiotrophoblast (A) and decidua (B) of control
and GDM placentas.
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Abbreviations
BMI Body Mass Index
CD31 Cluster of differentiation 31
CK7 Cytokeratin 7
CREB/CRTC2
cAMP responsive element binding protein 1/CREB
regulated transcriptional coactivator 2
DM2 Diabetes Mellitus Type 2
DMEM Dulbecco’s modified Eagle’s medium
EVT Extra-villous trophoblast cells
FBS Fetal bovine serum
FOXO1 Forkhead box protein O1
g Gramm
GDM Gestational Diabetes Mellitus
h Hours
H3K4me3 Trimethylation of Histone 3 at lysine 4
H3K9ac Acetylation of Histone 3 at lysine 9
HAT Histone acetyltransferase
HDAC Histone deacetylase
HOMA-IR Homeostatic model assessment—insulin resistance
HVT Human villous trophoblast cells
IRS Immunoreactivity score
LGA Large for gestational age
M Molar
mRNA Messanger ribonuclease
ncRNA Non-coding ribonuclease
oGTT Oral glucose tolerance test
OR Odds ratio
PTM Post-translational modifications
RR Relative Risk
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SCT Syncytiotrophoblast
TFIID Transcription factor II D
TSS Transcriptional start site
VDR Vitamin D receptor
VEGF-A Vascular endothelial growth factor A
Vit. D Vitamin D
WB Western Blot
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